El-Lakkany et al. showed that combined use of NAC and metformin in livers with NAFLD reduces the concentrations of TGF-β, TNF-α, and other inflammatory mediators and decreases oxidative stress [52]. The gene discussed is TGFB1; the disease is metabolic dysfunction-associated steatotic liver disease.